The post AVAX Price Prediction: Targets $15.50-$16.50 by Mid-February Despite Current Consolidation appeared on BitcoinEthereumNews.com. Rongchai Wang Jan 28The post AVAX Price Prediction: Targets $15.50-$16.50 by Mid-February Despite Current Consolidation appeared on BitcoinEthereumNews.com. Rongchai Wang Jan 28

AVAX Price Prediction: Targets $15.50-$16.50 by Mid-February Despite Current Consolidation



Rongchai Wang
Jan 28, 2026 14:49

Avalanche (AVAX) trades at $12.07 with analysts projecting 28-37% upside to $15.50-$16.50 range within 2-3 weeks despite neutral RSI and bearish MACD momentum signals.

Avalanche (AVAX) continues to consolidate near the $12 level as traders await the next directional move. With current technical indicators showing mixed signals and recent analyst forecasts pointing toward potential upside, this AVAX price prediction examines whether the cryptocurrency can break above its current range.

AVAX Price Prediction Summary

Short-term target (1 week): $11.77-$12.03
Medium-term forecast (1 month): $15.50-$16.50 range
Bullish breakout level: $12.69
Critical support: $11.27

What Crypto Analysts Are Saying About Avalanche

Recent analyst coverage suggests cautious optimism for Avalanche’s near-term prospects. Timothy Morano noted on January 26, 2026, that “Avalanche (AVAX) shows consolidation near $11.78 with analysts projecting 12-19% upside to $15.50-$16.50 range within 2-3 weeks despite current bearish momentum.”

MEXC News echoed similar sentiment on January 24, stating their “AVAX price prediction anticipates a move to $15.50-$16.50 within the next 2-3 weeks, representing 12-19% upside potential from current levels.”

However, shorter-term forecasts remain more conservative. CoinCodex projects Avalanche will reach $11.77 by January 31, 2026, representing modest 0.87% growth, while DigitalCoinPrice forecasts $12.03 for January 29, indicating a slight -0.87% change from current levels.

AVAX Technical Analysis Breakdown

Trading at $12.07, Avalanche sits in a critical technical zone with mixed momentum indicators. The RSI reading of 41.13 places AVAX in neutral territory, neither overbought nor oversold, suggesting room for movement in either direction.

The MACD histogram at 0.0000 indicates bearish momentum, with the MACD line (-0.4360) matching its signal line exactly. This convergence often precedes directional moves, making the next few sessions crucial for determining AVAX’s trajectory.

Bollinger Bands analysis shows AVAX trading in the lower portion of its range, with a %B position of 0.27. The current price sits well below the middle band at $12.96, indicating the cryptocurrency remains in a downward trend within its established channel.

Key moving averages paint a mixed picture. While AVAX trades above its 7-day SMA ($11.97), it remains below both the 20-day ($12.96) and 50-day ($12.94) averages. The significant gap to the 200-day SMA at $20.08 highlights the longer-term bearish trend that began in 2024.

Critical trading levels show immediate resistance at $12.38, followed by stronger resistance at $12.69. On the downside, support lies at $11.67 with stronger support at $11.27.

Avalanche Price Targets: Bull vs Bear Case

Bullish Scenario

The Avalanche forecast turns bullish upon a decisive break above $12.69 resistance. This level aligns with recent analyst projections targeting the $15.50-$16.50 range, representing 28-37% upside potential.

For this bullish scenario to unfold, AVAX needs RSI to climb above 50 and MACD to generate a positive crossover. A break above the 20-day moving average at $12.96 would provide additional technical confirmation, potentially triggering momentum toward the upper Bollinger Band at $14.87.

The daily Average True Range of $0.65 suggests sufficient volatility exists for such moves, particularly if broader cryptocurrency markets provide supportive conditions.

Bearish Scenario

Failure to hold current support levels could trigger a deeper correction. The immediate downside target sits at $11.67, with more significant support at $11.27. A break below this level could expose AVAX to further weakness toward the lower Bollinger Band at $11.06.

Given the bearish MACD momentum and position below key moving averages, this scenario remains viable if broader market conditions deteriorate or if Avalanche fails to generate positive catalysts.

Should You Buy AVAX? Entry Strategy

Based on current technical conditions, a phased approach appears most prudent for this AVAX price prediction. Initial positions could be considered near current levels around $12.07, with additional purchases on any dip toward the $11.67 support level.

Stop-loss orders should be placed below $11.27 to limit downside risk, representing approximately 7% from current levels. This approach allows participation in potential upside while managing risk appropriately.

For more aggressive traders, waiting for a confirmed break above $12.69 resistance might provide better risk-adjusted entry points, though at the cost of missing early move participation.

Conclusion

This AVAX price prediction suggests moderate optimism for the coming weeks, with analyst targets of $15.50-$16.50 providing compelling upside potential. However, current technical indicators show mixed signals that warrant cautious positioning.

The key catalyst will be AVAX’s ability to break above $12.69 resistance with conviction. Success at this level could trigger the projected 28-37% rally, while failure might extend current consolidation or trigger deeper correction.

Disclaimer: Cryptocurrency price predictions are highly speculative and subject to extreme volatility. This analysis is for informational purposes only and should not be considered financial advice. Always conduct your own research and consider your risk tolerance before making investment decisions.

Image source: Shutterstock

Source: https://blockchain.news/news/20260128-price-prediction-avax-targets-1550-1650-by-mid-february

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26